Abstract

Arterial hypertension is the most common chronic disorder in economically developed countries leading to chronic disability and lethal outcome.During the recent years the attention of the researchers was focused on identifying new endogenous substances involved in vasoconstriction and vasodilation mechanisms. In this direction special attention is paid to vasodilating products of epoxygenic metabolism such as epoxyeicosatrienoic acids (EETs), whose rapid conversion in the body into less active metabolites such as dihydroxyeicosatrienoic acids (DHETs) is promoted by enzymatic epoxide hydrolase (sHE).According literature sounces biologically active substance of plant origin – luteolin has the ability to inhibit sEH action, promoting the prolongation of EETs vasodilating activity. In the treatment of arterial hypertension, special attention is paid to the ability of the patient to use the drug independently, without any additional materials (water, syringe, etc.) and rapid action.Based on artificial intelligence and biopharmaceutical studies, the formulation of luteolin orodispersible tablets and its technology was developed by sublimation method.As it was shown ODT of luteolin meet standard requirements in terms of quality. The use of camphor as a sublimation agent ensures the formation of a porous structure, which promotes the penetration of fluid into the tablets and their fast disintegration.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call